Prolight has obtained subscription commitments for exercising warrants of series TO6 from, among others, members of the Board and management of approximately SEK 1.0 million
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
Prolight Diagnostics AB (publ) (“Prolight” or the “Company”) hereby announces that the Company has obtained subscription commitment agreements for the exercise of warrants of series TO6, among others, members of the Board and management in the Company, an investment of approximately SEK 1.0million, corresponding to approximately 4.7 percent of the total amount of outstanding warrants of series TO6. The exercise period for the warrants of series TO6 is currently ongoing and will continue up until May 31, 2024.
The Board and management in the Company, among others, intend to exercise 10,204,116 warrants of series TO6, corresponding to a total of approximately SEK 1.0 million. If all the warrants of series TO6 are exercised, the Company will receive approximately SEK 21.8 million before issuing costs.
Summarized terms for the warrants of series TO6:
Exercise period: May 20, 2024 – May 31, 2024.
Exercise price: SEK 0.10 per share.
Issue size: 217,513,494 warrants of series TO6 entitling to subscription of 217,513,494 shares. If all the warrants are exercised the Company will receive approximately SEK 21.8 million before issuing costs.
Note that the warrants that are not exercised at latest on May 31, 2024, will expire without value. For the warrants not to lose their value, the holder must actively exercise the warrants for subscription of new shares. Please observe that certain nominees might close their application earlier than May 31, 2024.
Shares, share capital, and dilution
If all warrants of series TO6 are exercised the total number of shares in the Company will increase by 217,513,494, from 499,782,948 shares to 717,296,442 shares, and the share capital will increase with SEK 21,751,349.40, from SEK 49,978,294.80, to SEK 71,729,644.20. This corresponds to a maximum dilution of approximately 30.3 percent of the total number of shares and 30.3 percent of the total number of votes in the Company. The dilution effect has been calculated as the number of additional shares and votes, respectively, in relation to the number of existing and additional shares and votes, respectively.
How the warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscription will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.prolightdx.com.
Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the exercise of the warrants of series TO6.